title: Control of bleeding in surgical procedures: critical appraisal of HEMOPATCH (Sealing Hemostat).
abstract: The need for advanced hemostatic agents increases with the complexity of surgical procedures and use of anticoagulation and antiplatelet treatments. HEMOPATCH (Sealing Hemostat) is a novel, advanced hemostatic pad that is composed of a synthetic, protein-reactive monomer and a collagen backing. The active side is covered with a protein-reactive monomer: N-hydroxysuccinimide functionalized polyethylene glycol (NHS-PEG). NHS-PEG rapidly affixes the collagen pad to tissue to promote and maintain hemostasis. The combined action of the NHS-PEG and collagen is demonstrated to have benefit relative to other hemostatic agents in surgery and preclinical surgical models. This paper reviews the published investigations and case reports of the hemostatic efficacy of HEMOPATCH, wherein HEMOPATCH is demonstrated to be an effective, easy-to-use hemostatic agent in open and minimally invasive surgery of patients with thrombin- or platelet-induced coagulopathies.
authors.affiliation: Preclinical Safety and Efficacy, Baxter Healthcare Corporation, Deerfield, IL, USA.
authors.forename: Kevin Michael
authors.initials: KM
authors.lastname: Lewis
authors.affiliation: Medical Affairs, Baxter Healthcare SA, Zurich, Switzerland.
authors.forename: Carl Erik
authors.initials: CE
authors.lastname: Kuntze
authors.affiliation: Surgical Sciences and Engineering, Baxter Medical Products GmbH, Vienna, Austria.
authors.forename: Heinz
authors.initials: H
authors.lastname: Gulle
keywords: HEMOPATCH; hemostasis; sealing; surgical hemostasis; surgical sealant